Bristol Myers’ KarXT shows positive results in schizophrenia

Bristol Myers announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting May 28-31 in Miami. Research to be presented at the meeting continues to demonstrate the potential of KarXT as a differentiated treatment option for adults living with schizophrenia. Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over long-term trials in adults with schizophrenia. In-trial qualitative interviews found that the majority of participants treated with KarXT in the long-term EMERGENT-5 trial perceived improvements in positive, negative and cognitive symptoms of schizophrenia. The incidence of extrapyramidal symptoms adverse events deemed to be treatment-related was 1% and the most commonly reported treatment-related EPS AE was akathisia. KarXT was not associated with clinically meaningful changes from baseline in movement disorder scale scores over short or long-term studies. Initial findings showed participants perceived an improvement in positive, negative, and cognitive symptoms of schizophrenia since initiating KarXT.